Drug intelligence / Profile preview

Shugan Jieyu

Development stage
Phase 3
Lead developer
Chengdu Kanghong Pharmaceutical
Modality
Small Molecules, Device-based Delivery → Drug Delivery Systems
Administration
Oral
01

Overview

Shugan Jieyu (Shugan Jieyu Capsule) is a proprietary Chinese medicine composed primarily of *Hypericum perforatum* (St. John's Wort) and *Acanthopanax senticosus* (Siberian Ginseng)[3][4][6][7]. It is approved in China for the treatment of depression and has also been studied for use in generalized anxiety disorder, essential hypertension with insomnia or anxiety/depression, and psychiatric symptoms associated with epilepsy[2][4][5][7]. The mechanism of action is believed to involve modulation of neurotransmitters such as serotonin and dopamine, regulation of the hypothalamic-pituitary-adrenal axis, neuroprotection via immune system modulation, anti-fatigue effects from Acanthopanax senticosus, and alteration of gut microbiota composition[2][6][8]. Modern pharmacological studies attribute antidepressant effects to hypericin from Hypericum perforatum[2], while Acanthopanax senticosus contributes adaptogenic properties. Shugan Jieyu was approved by the China Food and Drug Administration in 2008 for clinical prescription in depression[4].

Brand names
Shugan Jieyu CapsuleJieyu Capsule
Other names
Jieyu Capsule
02

Targets

AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)CASP3 (Caspase-3)IL1B (Interleukin-1 beta)IL-6 (Interleukin 6)JUN (Transcription factor Jun)MAPK3 (Mitogen-activated protein kinase 1)VEGFA (Vascular endothelial growth factor A)DAT (Dopamine plasma membrane transport protein)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on Shugan Jieyu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shugan Jieyu.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call